Anti-IL17 therapies for psoriasis

References

• Parisi R, Symmons DP, Griffiths CE, et al. Identification and Management of Psoriasis and Associated ComorbidiTy (IMPACT) project team. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133:377–385.
   PubMed Web of Science ®Google Scholar
• Nestle F, Kaplan D, Barker J. Psoriasis. N Engl J Med. 2009;361(5):496–509.
   PubMed Web of Science ®Google Scholar
• Greb J, Goldminz A, Elder J, et al. Psoriasis. Nat Rev Dis Primers. 2016;2:1–17.
   Web of Science ®Google Scholar
• Braun-Falco O, Burg G. Inflammatory infiltrate in psoriasis vulgaris. A cytochemical study. Arch Klin Exp Dermatol. 1970;236:297–314.
   PubMedGoogle Scholar
• Cai Y, Fleming C, Yan J. New insights of T cells in the pathogenesis of psoriasis. Cell Mol Immunol. 2012;9(4):302–309.
   PubMed Web of Science ®Google Scholar
• Fitch E, Harper E, Skorcheva I, et al. Pathophysiology of psoriasis: recent advances on IL-23 and Th17 cytokines. Curr Rheumatol Rep. 2007;9:461–467.
   PubMedGoogle Scholar
• Lower M, Russell C, Martin D, et al. The IL-23/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses. Trends Immunol. 2013;34(4):174–181.
   PubMed Web of Science ®Google Scholar
• Sivamani RK, Correa G, Ono Y, et al. Biological therapy of psoriasis. Indian J Dermatol. 2010;55(2):161–170.
   PubMedGoogle Scholar
• Miossec P, Kolls J. Targeting IL-17 and TH17 cells in chronic inflammation. Nat Rev Drug Discov. 2012;11:763–776.
   PubMed Web of Science ®Google Scholar
• Malakouti M, Brown G, Wang E, et al. The role of IL-17 in psoriasis. J Dermatol Treat. 2015;26(1):41–44.
   PubMed Web of Science ®Google Scholar
• Wilson N, Boniface K, Chan J, et al. Development, cytokine profile and function of human interleukin 17-producing helper T-cells. Nat Immunol. 2007;8(9):950–957.
   PubMed Web of Science ®Google Scholar
• Ghoreschi K, Laurence A, Yang X, et al. T helper 17 cell heterogeneity and pathogenicity in autoimune disease. Trends Immunol. 2011;32:395–401.
   PubMed Web of Science ®Google Scholar
• Lynde C, Poulin Y, Vender R, et al. Interleukin 17A: toward a new understanding of psoriasis pathogenesis. J Am Acad Dermatol. 2014;71(1):141–150.
   PubMed Web of Science ®Google Scholar
• Cosentyx (secukinumab) [package insert]. Switzerland: Novartis Pharmaceutical Corporation; 2016.
   Google Scholar
• Langley R, Elewski B, Lebwohl M, et al. Secukinumab in plaque psoriasis – results of two phase 3 trials. N Engl J Med. 2014 Jul 24;371(4):326–338.
   PubMed Web of Science ®Google Scholar
• Jeon C, Sekhon S, Yan D, et al. Monoclonal antibodies inhibiting IL-12, −23, and −17 for the treatment of psoriasis. Hum Vaccin Immunother. 2017;13(10):2247–2259.
   PubMed Web of Science ®Google Scholar
• Amin M, Darji K, No D, et al. Review of IL-17 inhibitors for psoriasis. J Dermatological Treat. 2018;29(4):347–352.
   PubMed Web of Science ®Google Scholar
• Griffiths C, Papp K, Zaldivar R, et al. Secukinumab shows efficacy in subjects regardless of previous exposure to biologic therapy: a pooled subanalysis from four phase 3 clinical trials in psoriasis (poster 1760) [Poster]. Poster presented at 73rd AAD Annual Meeting. 2015. San Francisco, CA.
   Google Scholar
• Mrowietz U, Leonardi C, Girolomoni G, et al. Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: a randomized, double-blind, noninferiority trial (SCULPTURE). J Am Acad Dermatol. 2015 Jul;73(1):27–36.
   PubMed Web of Science ®Google Scholar
• Bissonnette R, Luger T, Thaci D, et al. Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE extension study). J Eur Acad Dermatol Venereol. 2018;32(9):1507–1514.
   Web of Science ®Google Scholar
• Thaci D, Humeniuk K, Frambach Y, et al. Secukinumab in psoriasis: randomized, controlled phase 3 trial results assessing the potential to improve treatment response in partial responders (STATURE). Br J Dermatol. 2015 Sept;173(3):777–787.
   PubMed Web of Science ®Google Scholar
• Abrouk M, Gandy JR, Nakamura M, et al. Secukinumab in the treatment of psoriasis and psoriatic arthritis: a review of the literature. Skin Therapy Lett. 2017;22(4):1–6.
   PubMedGoogle Scholar
• Blauvelt A, Reich K, Tsai T, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: results from the CLEAR study. J Am Acad Dermatol. 2017 Jan;76(1):60–69.
   PubMed Web of Science ®Google Scholar
• Thaci D, Blauvelt A, Reich K, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J Am Acad Dermatol. 2015;73(3):400–409.
   PubMed Web of Science ®Google Scholar
• Bagel J, Duffin K, Moore A, et al. The effect of secukinumab on moderate-to-severe scalp psoriasis: results of a 24-week, randomized, double-blind, placebo-controlled phase 3b study. J Am Acad Dermatol. 2017 Oct;77(4):667–674.
   PubMed Web of Science ®Google Scholar
• Reich K, Jazayeri S, Augustin M, et al. Secukinumab shows high and sustained efficacy in nail psoriasis: week 80 results from the TRANSFIGURE study. J Am Acad Dermatol. 2017;76(6suppl 1):AB232.
   Google Scholar
• Gottlieb A, Sullivan J, van Doorn M, et al. Secukinumab shows significant efficacy in palmoplantar psoriasis: results from GESTURE, a randomized controlled trial. J Am Acad Dermatol. 2017 Jan;76(1):70–80.
   PubMed Web of Science ®Google Scholar
• Imafuku S, Honma M, Okubo Y, et al. Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: A 52-week analysis from phase III open-label multicenter Japanese study. J Dermatol. 2016 Sept;43(9):1011–1017.
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Iversen L, Eidsmo L, et al. Long-term psoriasis control following secukinumab discontinuation indicated disease modification of moderate to severe psoriasis. Presented at: 13th Annual Maui Derm for Dermatologists; 2017 Mar 20–24; Maui, Hawaii.
   Google Scholar
• Mease PJ, McInnes IB, Kirkham B, et al. Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis. N Engl J Med. 2015;373(14):1329–1339.
   PubMed Web of Science ®Google Scholar
• McInnes IB, Mease PJ, Kirkham B, et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;386:1137–1146.
   PubMed Web of Science ®Google Scholar
• McInnes IB, Mease PJ, Ritchlin CT, et al. Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study. Rheumatology (Oxford). 2017;56(11):1993–2003.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Kavanaugh A, Reimold A, et al. Secukinumab provides sustained improvements in the signs and symptoms of active psoriatic arthritis through three years: efficacy and safety results from a phase 3 trial [Abstract]. Arthritis Rheumatol. 2016;68(suppl):10.
   Google Scholar
• Bissonnette R, Luger T, Thaci D, et al. Secukinumab sustains good efficacy and favourable safety in moderate-to-severe psoriasis after up to 3 years of treatment: results from a double-blind extension study. Br J Dermatol. 2017 Oct;177(4):1033–1042.
   PubMed Web of Science ®Google Scholar
• Paul C, Lacour JP, Tedremets L, et al. Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE). J Eur Acad Dermatol Venereol. 2015;29(6):1082–1090.
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Prinz JC, Gottlieb AB, et al. Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE). Br J Dermatol. 2015;172(2):484–493.
   PubMed Web of Science ®Google Scholar
• Chandrakumar SF, Yeung J. Interleukin-17 antagonists in the treatment of psoriasis. J Cutan Med Surg. 2015;19(2):109–114.
   PubMed Web of Science ®Google Scholar
• Taltz™ (ixekizumab) [package insert]. Indianapolis, IN: FDA: Eli Lilly and Company; 2016.
   Google Scholar
• Griffiths CE, Reich K, Lebwohl M, et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet. 2015;386:541–551.
   PubMed Web of Science ®Google Scholar
• Gordon K, Blauvelt A, Papp K, et al. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med. 2016;375:345–356.
   PubMed Web of Science ®Google Scholar
• Leonardi C, Maari C, Philipp S, et al. Maintenance of skin clearance with ixekizumab treatment of psoriasis: three-year results from the UNCOVER-3 study. J Am Acad Dermatol. 2018;79(5):824–830.e2.
   Web of Science ®Google Scholar
• Reich K, Pinter A, Lacour J, et al. Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase III study. Br J Dermatol. 2017 Oct;177(4):1014–1023.
   PubMed Web of Science ®Google Scholar
• Zachariae C, Gordon K, Kimball A, et al. Efficacy and safety of ixekizumab over 4 years of open-label treatment in a phase 2 study in chronic plaque psoriasis. J Am Acad Dermatol. 2018 Aug;79(2):294–301.e6.
   PubMed Web of Science ®Google Scholar
• Reich K, Leonardi C, Lebwohl M, et al. Sustained response with ixekizumab treatment of moderate-to-severe psoriasis with scalp involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2, UNCOVER-3). J Dermatolog Treat. 2017 Jun;28(4):282–287.
   PubMed Web of Science ®Google Scholar
• Ryan C, Menter A, Guenther L, et al. Efficacy and safety of ixekizumab in a randomized, double‐blinded, placebo‐controlled phase IIIb study of patients with moderate‐to‐severe genital psoriasis. Br J Dermatol.  2018 Oct;179(4):844–852.
   Google Scholar
• Menter A, Warren R, Langley R, et al. Efficacy of ixekizumab compared to etanercept and placebo in patients with moderate-to-severe plaque psoriasis and non-pustular palmoplantar involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2, and UNCOVER-3). J Eur Acad Dermatol Venereol. 2017 Oct;31(10):1686–1692.
   PubMed Web of Science ®Google Scholar
• Saeki H, Nakagawa H, Nakajo K, et al. Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: results from a 52-week, open-label, phase 3 study (UNCOVER-J). J Dermatol. 2017 Apr;44(4):355–362.
   PubMed Web of Science ®Google Scholar
• Nash P, Kirkham B, Okada M, et al. Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial. Lancet. 2017;389(10086):2317–2327.
   PubMed Web of Science ®Google Scholar
• Mease PJ, van der Heijde D, Ritchlin CT, et al. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. Ann Rheum Dis. 2016;76(1):79–87.
   PubMed Web of Science ®Google Scholar
• Papp K, Bachelez H, Blauvelt A, et al. Infections from seven clinical trials of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriasis. Br J Dermatol. 2017 Dec;177(6):1537–1551.
   PubMed Web of Science ®Google Scholar
• Strober B, Leonardi C, Papp K, et al. Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: etanercept comparisons and integrated data. J Am Acad Dermatol. 2017;76:432–440.
   PubMed Web of Science ®Google Scholar
• Reich K, Leonardi C, Langley R, et al. Inflammatory bowel disease among patients with psoriasis treated with ixekizumab: a presentation of adjudicated data from an integrated database of 7 randomized controlled and uncontrolled trials. J Am Acad Dermatol. 2017;76(3):441–448.
   PubMed Web of Science ®Google Scholar
• Siliq™ (brodalumab) [package insert]. Bridgewater,NJ: Valeant Pharmaceuticals North America LLC; 2017.
   Google Scholar
• Lebwohl M, Strober B, Menter A, et al. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. N Engl J Med. 2015 Oct;373(14):1318–1328.
   PubMed Web of Science ®Google Scholar
• Papp K, Reich K, Paul C, et al. A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2016 Aug;175(2):273–286.
   PubMed Web of Science ®Google Scholar
• Gottlieb A, Gordon K, Hsu S, et al. Improvement in itch and other psoriasis symptoms with brodalumab in phase 3 randomized controlled trials. J Eur Acad Dermatol Venereol. 2018;32:1305–1313.
   Web of Science ®Google Scholar
• Papp K, Leonardi C, Menter A, et al. Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatment. J Am Acad Dermatol. 2014 Dec;71(6):1183–1190.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Genovese MC, Greenwald MW, et al. Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis. N Engl J Med. 2014;370(24):2295–2306.
   PubMed Web of Science ®Google Scholar
• Chiricozzi A, Romanelli M, Saraceno R, et al. No meaningful association between suicidal behavior and the use of IL-17A-neutralizing or IL-17RA-blocking agents. Expert Opin Drug Saf. 2016 Dec;15(12):1653–1659.
   PubMed Web of Science ®Google Scholar
• Gooderham M, Gavino‐Velasco J, Clifford C, et al. A review of psoriasis, therapies, and suicide. J Cutan Med Surg. 2016;20:293–303.
   PubMed Web of Science ®Google Scholar
• Singh S, Taylor C, Kornmehl H, et al. Psoriasis and suicidality: a systematic review and meta-analysis. J Am Acad Dermatol. 2017;77(3):425–40.e2.
   PubMed Web of Science ®Google Scholar
• Dalgard FJ, Gieler U, Tomas‐Aragones L, et al. The psychological burden of skin diseases: a cross‐sectional multicenter study among dermatological out‐patients in 13 European countries. J Invest Dermatol. 2015;135(4):984–991.
   PubMed Web of Science ®Google Scholar
• Kurd SK, Troxel AB, Crits‐Christoph P, et al. The risk of depression, anxiety, and suicidality in patients with psoriasis: a population‐based cohort study. Arch Dermatol. 2010;146(8):891–895.
   PubMed Web of Science ®Google Scholar
• Dowlatshahi EA, Wakkee M, Arends LR, et al. The prevalence and odds of depressive symptoms and clinical depression in psoriasis patients: a systematic review and meta‐analysis. J Invest Dermatol. 2014;134(6):1542–1551.
   PubMed Web of Science ®Google Scholar
• Strober B, Gooderham M, de Jong EMGJ, et al. Depressive symptoms, depression, and the effect of biologic therapy among patients in Psoriasis Longitudinal Assessment and Registry (PSOLAR). J Am Acad Dermatol. 2018;78(1):70–80.
   PubMed Web of Science ®Google Scholar
• Mease P, van der Heijde D, Landewé R, et al. Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study. Ann Rheum Dis. 2018;77(6):890–897.
   PubMed Web of Science ®Google Scholar
• Papp K, Gordon K, Langley R, et al. Impact of previous biologic use on the efficacy and safety of brodalumab and ustekinumab in patients with moderate‐to‐severe plaque psoriasis: integrated analysis of the randomized controlled trials AMAGINE‐2 and AMAGINE‐3. Br J Dermatol. 2018;179(2):320–328.
   Web of Science ®Google Scholar
• Glatt S, Baeten D, Baker T, et al. Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation. Ann Rheum Dis. 2018;77:523–532.
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Papp K, Lebwohl M, et al. Rapid onset of action in patients with moderate-to-severe psoriasis treated with brodalumab: a pooled analysis of data from two phase 3 randomized clinical trials (AMAGINE-2 and AMAGINE-3). J Am Acad Dermatol. 2017 Aug;77(2):372–374.
   PubMed Web of Science ®Google Scholar
• Natsis NE, Gottlieb AB. Bimekizumab for the treatment of psoriatic disease. Expert Opin Biol Ther. 2018;18(12):1193–1197.
   PubMed Web of Science ®Google Scholar
• Papp KA, Merola JF, Gottlieb AB, et al. Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trail. J Am Acad Dermatol. 2018;79(2):277–286.
   PubMed Web of Science ®Google Scholar
• Blauvelt A. Safety of secukinumab in the treatment of psoriasis. Expert Opin Drug Saf. 2016;15(10):1413–1420.
   PubMed Web of Science ®Google Scholar
• Hohenberger M, Cardwell L, Oussedik E, et al. Interleukin-17 inhibition: role in psoriasis and inflammatory bowel disease. J Dermatological Treat. 2018;29(1):13–18.
   PubMed Web of Science ®Google Scholar
• van de Kerkhof PC, Griffiths CE, Reich K, et al. Secukinumab long-term safety experience: a pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis. J Am Acad Dermatol. 2016;75(1):83–98.e4.
   PubMed Web of Science ®Google Scholar
• Tang C, Kakuta S, Shimizu K, et al. Suppression of IL-17F, but not of IL-17A, provides protection against colitis by inducing treg cells through modification of the intestinal microbiota. Nat Immunol. 2018;19(7):755–765.
   PubMed Web of Science ®Google Scholar